HRMY
Harmony Biosciences Holdings, Inc. NASDAQ Listed Aug 19, 2020$31.42
Mkt Cap $1.8B
52w Low $25.52
38.4% of range
52w High $40.87
50d MA $29.11
200d MA $32.94
P/E (TTM)
11.5x
EV/EBITDA
6.4x
P/B
2.1x
Debt/Equity
0.3x
ROE
18.2%
P/FCF
6.2x
RSI (14)
—
ATR (14)
—
Beta
0.89
50d MA
$29.11
200d MA
$32.94
Avg Volume
956.2K
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
630 West Germantown Pike · Plymouth Meeting, PA 19462 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 32.78 | -11.7% | -4.1% | — | — | — | — | — |
| Feb 24, 2026 | AMC | 0.84 | 0.38 | -54.8% | 28.19 | -1.1% | +0.0% | +3.1% | -1.8% | +1.3% | -2.2% | — |
| Nov 4, 2025 | AMC | 0.92 | 0.87 | -5.4% | 30.72 | -1.3% | +2.1% | -1.3% | +1.6% | +1.2% | +3.6% | — |
| Aug 5, 2025 | AMC | 0.78 | 0.68 | -12.8% | 34.94 | +0.8% | -0.8% | -1.4% | +0.0% | +1.8% | +1.9% | — |
| May 6, 2025 | AMC | 0.59 | 0.78 | +32.2% | 32.05 | +0.5% | +4.3% | +1.9% | -0.1% | +4.7% | -3.6% | — |
| Feb 25, 2025 | AMC | 0.74 | 0.85 | +14.9% | 36.97 | -2.5% | -9.5% | -2.2% | +3.4% | -4.9% | +1.3% | — |
| Oct 29, 2024 | AMC | 0.67 | 0.79 | +17.9% | 41.49 | -9.6% | -18.5% | -4.9% | +3.0% | -0.1% | +1.1% | — |
| Aug 6, 2024 | AMC | -0.06 | 0.20 | +433.3% | 32.83 | +0.9% | +2.2% | +1.3% | -0.4% | -1.3% | +5.0% | — |
| Apr 30, 2024 | AMC | 0.60 | 0.67 | +11.7% | 30.91 | -1.6% | -2.1% | +4.7% | -0.4% | -2.1% | +1.5% | — |
| Feb 22, 2024 | AMC | 0.48 | 0.45 | -6.2% | 31.45 | -1.1% | +3.3% | -0.1% | +3.1% | -0.7% | -3.5% | — |
| Oct 31, 2023 | AMC | 0.65 | 0.75 | +15.4% | 23.54 | +1.6% | +4.2% | +0.4% | +5.2% | -3.8% | -2.3% | — |
| Aug 1, 2023 | AMC | 0.63 | 0.56 | -11.1% | 33.99 | -0.9% | -4.2% | +0.0% | +3.2% | -0.3% | -0.6% | — |
| May 2, 2023 | AMC | 0.44 | 0.48 | +9.1% | 33.55 | +4.5% | +7.3% | -1.2% | +0.9% | +0.5% | +1.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 25 | UBS | Maintains | Neutral → Neutral | — | $28.19 | $27.89 | -1.1% | +0.0% | +3.1% | -1.8% | +1.3% | -2.2% |
| Feb 25 | BofA Securities | Maintains | Underperform → Underperform | — | $28.19 | $27.89 | -1.1% | +0.0% | +3.1% | -1.8% | +1.3% | -2.2% |
| Feb 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.19 | $27.89 | -1.1% | +0.0% | +3.1% | -1.8% | +1.3% | -2.2% |
| Feb 25 | Needham | Maintains | Buy → Buy | — | $28.19 | $27.89 | -1.1% | +0.0% | +3.1% | -1.8% | +1.3% | -2.2% |
| Feb 11 | UBS | Downgrade | Buy → Neutral | — | $37.93 | $37.08 | -2.2% | -3.5% | -2.0% | +0.4% | +2.5% | -4.4% |
| Jan 8 | Truist | Maintains | Buy → Buy | — | $37.55 | $37.55 | +0.0% | +0.9% | +1.8% | -0.7% | -6.6% | +0.8% |
| Dec 1 | Mizuho | Maintains | Outperform → Outperform | — | $35.29 | $35.60 | +0.9% | +0.6% | +1.4% | +2.7% | +3.4% | +4.1% |
| Nov 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.31 | $34.50 | +0.6% | +2.8% | +0.2% | +0.6% | -0.8% | +0.6% |
| Nov 24 | Needham | Maintains | Buy → Buy | — | $34.31 | $34.50 | +0.6% | +2.8% | +0.2% | +0.6% | -0.8% | +0.6% |
| Nov 6 | Mizuho | Maintains | Outperform → Outperform | — | $31.35 | $31.50 | +0.5% | -1.3% | +1.6% | +1.2% | +3.6% | +1.7% |
| Oct 15 | UBS | Maintains | Buy → Buy | — | $26.84 | $26.67 | -0.6% | -0.8% | -2.6% | -0.2% | +0.5% | +0.5% |
| Sep 25 | Mizuho | Maintains | Outperform → Outperform | — | $26.76 | $26.71 | -0.2% | +1.0% | +1.7% | +0.5% | -0.3% | -2.3% |
| Sep 25 | Deutsche Bank | Maintains | Buy → Buy | — | $26.76 | $26.71 | -0.2% | +1.0% | +1.7% | +0.5% | -0.3% | -2.3% |
| Sep 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.76 | $26.71 | -0.2% | +1.0% | +1.7% | +0.5% | -0.3% | -2.3% |
| Sep 24 | Needham | Maintains | Buy → Buy | — | $32.07 | $29.92 | -6.7% | -16.6% | +1.0% | +1.7% | +0.5% | -0.3% |
| Jul 10 | Deutsche Bank | Maintains | Buy → Buy | — | $34.29 | $34.35 | +0.2% | +0.1% | -1.0% | +2.1% | +0.4% | +1.1% |
| May 15 | Mizuho | Maintains | Outperform → Outperform | — | $33.39 | $33.64 | +0.7% | +2.5% | +2.5% | +2.4% | -0.8% | -3.1% |
| May 7 | Needham | Maintains | Buy → Buy | — | $32.05 | $32.20 | +0.5% | +4.3% | +1.9% | -0.1% | +4.7% | -3.6% |
| May 6 | Needham | Maintains | Buy → Buy | — | $29.96 | $31.11 | +3.8% | +7.0% | +4.3% | +1.9% | -0.1% | +4.7% |
| Apr 28 | UBS | Maintains | Buy → Buy | — | $29.61 | $29.58 | -0.1% | -0.8% | +0.3% | +0.1% | +1.3% | +1.5% |
| Apr 10 | Needham | Maintains | Buy → Buy | — | $29.07 | $29.00 | -0.2% | -0.3% | +0.6% | +1.2% | -2.6% | -2.8% |
| Apr 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.40 | $29.31 | +3.2% | -1.0% | +3.3% | -0.3% | +0.6% | +1.2% |
| Apr 8 | Needham | Maintains | Buy → Buy | — | $28.40 | $29.31 | +3.2% | -1.0% | +3.3% | -0.3% | +0.6% | +1.2% |
| Mar 18 | Mizuho | Maintains | Outperform → Outperform | — | $34.32 | $34.32 | +0.0% | +1.3% | -1.1% | +1.5% | +1.1% | -2.9% |
| Feb 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.47 | $33.55 | +0.2% | -2.2% | +3.4% | -4.9% | +1.3% | +3.5% |
| Feb 26 | Needham | Maintains | Buy → Buy | — | $36.97 | $36.03 | -2.5% | -9.5% | -2.2% | +3.4% | -4.9% | +1.3% |
| Feb 25 | Needham | Maintains | Buy → Buy | — | $34.18 | $34.63 | +1.3% | +8.2% | -9.5% | -2.2% | +3.4% | -4.9% |
| Feb 20 | Mizuho | Maintains | Outperform → Outperform | — | $35.32 | $35.15 | -0.5% | -1.2% | -0.9% | -1.1% | +8.2% | -9.5% |
| Feb 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $39.09 | $36.82 | -5.8% | -9.6% | -1.2% | -0.9% | -1.1% | +8.2% |
| Feb 19 | Needham | Maintains | Buy → Buy | — | $39.09 | $36.82 | -5.8% | -9.6% | -1.2% | -0.9% | -1.1% | +8.2% |
| Jan 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $38.01 | $38.03 | +0.1% | +0.6% | +0.4% | +1.0% | +1.9% | -1.9% |
| Jan 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.93 | $36.93 | +0.0% | +4.4% | +1.3% | +3.6% | -4.4% | -1.7% |
| Jan 13 | Oppenheimer | Maintains | Outperform → Outperform | — | $33.86 | $35.42 | +4.6% | +7.6% | -0.1% | +1.4% | +4.4% | +1.3% |
| Jan 13 | Needham | Maintains | Buy → Buy | — | $33.86 | $35.42 | +4.6% | +7.6% | -0.1% | +1.4% | +4.4% | +1.3% |
| Oct 30 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $41.49 | $37.49 | -9.6% | -18.5% | -4.9% | +3.0% | -0.1% | +1.1% |
| Oct 30 | Oppenheimer | Maintains | Outperform → Outperform | — | $41.49 | $37.49 | -9.6% | -18.5% | -4.9% | +3.0% | -0.1% | +1.1% |
| Oct 30 | Needham | Maintains | Buy → Buy | — | $41.49 | $37.49 | -9.6% | -18.5% | -4.9% | +3.0% | -0.1% | +1.1% |
| Oct 29 | Needham | Maintains | Buy → Buy | — | $35.75 | $37.58 | +5.1% | +16.1% | -18.5% | -4.9% | +3.0% | -0.1% |
| Oct 10 | Mizuho | Maintains | Outperform → Outperform | — | $33.60 | $34.00 | +1.2% | +3.6% | +0.1% | +1.9% | +0.1% | -1.9% |
| Oct 2 | Needham | Maintains | Buy → Buy | — | $39.24 | $39.22 | -0.1% | -9.4% | -2.2% | -0.5% | -0.6% | +1.1% |
| Sep 24 | Needham | Maintains | Buy → Buy | — | $38.25 | $38.31 | +0.2% | -1.1% | -1.4% | +6.7% | -1.7% | +2.2% |
| Sep 12 | Needham | Maintains | Buy → Buy | — | $37.28 | $37.60 | +0.9% | +1.3% | +3.0% | -0.4% | +0.1% | -1.2% |
| Aug 8 | Needham | Maintains | Buy → Buy | — | $33.55 | $34.00 | +1.3% | +1.3% | -0.4% | -1.3% | +5.0% | -1.8% |
| Aug 6 | Needham | Maintains | Buy → Buy | — | $30.92 | $32.00 | +3.5% | +6.2% | +2.2% | +1.3% | -0.4% | -1.3% |
| Jun 25 | Needham | Maintains | Buy → Buy | — | $30.10 | $30.01 | -0.3% | -0.1% | +3.3% | +1.3% | -4.2% | +0.8% |
| Jun 24 | Needham | Maintains | Buy → Buy | — | $30.13 | $30.28 | +0.5% | -0.1% | -0.1% | +3.3% | +1.3% | -4.2% |
| May 1 | Needham | Maintains | Buy → Buy | — | $30.91 | $30.42 | -1.6% | -2.1% | +4.7% | -0.4% | -2.1% | +1.5% |
| Apr 30 | Needham | Maintains | Buy → Buy | — | $29.25 | $31.65 | +8.2% | +5.7% | -2.1% | +4.7% | -0.4% | -2.1% |
| Apr 12 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $31.26 | $31.40 | +0.4% | -5.6% | +0.1% | +0.9% | -2.0% | -0.5% |
| Apr 11 | Needham | Maintains | Buy → Buy | — | $29.37 | $30.01 | +2.2% | +6.4% | -5.6% | +0.1% | +0.9% | -2.0% |
No insider trades available.
8-K · 2.02
!! High
Harmony Biosciences Holdings, Inc. -- 8-K 2.02: Earnings Results
Harmony Biosciences reported quarterly earnings results; investors should review the attached press release for specific financial performance metrics and guidance updates.
May 7
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Harmony's leadership transition to a new CFO could signal strategic shifts in financial management and capital allocation, potentially affecting investor confidence and operational direction.
Apr 14
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Leadership transitions at Harmony create execution risk and potential disruption, requiring investors to assess whether new management can maintain operational momentum and shareholder value.
Apr 2
8-K
Harmony Biosciences Holdings, Inc. -- 8-K Filing
I cannot provide a meaningful analysis as the summary lacks substantive information about the actual business event or transaction disclosed in this 8-K filing.
Feb 24
Data updated apr 25, 2026 2:02pm
· Source: massive.com